| ￥4500 | |
| Z06488-100 | |
|
|
|
|
|
|
|
|
|
| Species | Human | ||||||
| Protein Construction |
|
||||||
| Conjugate | Biotin | ||||||
| Purity | > 95% as determined by BisTris PAGE | ||||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||||
| Biological Activity | Measured by its binding ability in a functional ELISA.Test result was comparable to standard batch. | ||||||
| Expression System | HEK293 | ||||||
| Theoretical Molecular Weight | 50.2 kDa | ||||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 52-60 kDa based on Bis-Tris PAGE result. | ||||||
| Formulation | Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). | ||||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||||
| Storage & Stability | Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles. |
Immobilized HLA-A*03:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer[Biotin], His & Avi, Human, His Tag at 1 μg/ml (100 μl/well) on the streptavidin precoated plate(5 μg/ml). Dose response curve for Anti-HLA-A*03:01&B2M&KRAS G12V Antibody, hFc Tag with the EC50 of 0.24 μg/ml determined by ELISA. »
The purity of HLA-A*03:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer[Biotin], His & Avi, Human is greater than 95% as determined by SEC-HPLC. »
HLA-A*03:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer[Biotin], His & Avi, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »
HLA-A*03:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer[Biotin], His & Avi, Human, His Tag captured on CM5 Chip via anti-his antibody can bind Anti-HLA-A*03:01&B2M&KRAS G12V (VVVGAVGVGK) Antibody with an affinity constant of 0.14 μM as determined in SPR assay (Biacore T200). »
| Target Background | Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. |
| Synonyms | MHC; KRAS; K-Ras 2; KRAS2; C-K-RAS; CFC2; K-RAS2A; K-RAS2B; K-RAS4A; K-RAS4B; KRAS1; KRAS2; NS; NS3; RASK2; GTPase Kras; KI-RAS; RALD |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
